MLYS Stock: Price, Earnings History and SEC Filings
Mineralys Therapeutics, Inc. (MLYS) last traded at $18.18, down 14.41% on the latest session and down 27.7% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-2.85 against an analyst estimate of $-0.57, a miss of 400.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
MLYS earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 11, 2026 | $-2.85 | $-0.57 | -400.00% |
| Mar 2026 | May 6, 2026 | $-0.47 | $-0.51 | +7.84% |
| Dec 2025 | Mar 12, 2026 | $-0.40 | $-0.57 | +29.82% |
| Sep 2025 | Nov 10, 2025 | $-0.52 | $-0.66 | +21.21% |
MLYS beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How MLYS reacts to earnings
Across its last 8 earnings releases, MLYS moved 4.3% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-11 | After close | -1.02% |
| 2026-05-06 | After close | -2.56% |
| 2026-03-12 | After close | -2.96% |
| 2025-11-10 | After close | +5.87% |
| 2025-08-12 | After close | +0.37% |
| 2025-05-12 | After close | +1.20% |
| 2025-02-12 | Before open | +10.04% |
| 2024-11-12 | Before open | -10.32% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
MLYS financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | – | -$155M | – | – | $-2.29 |
| 2024 | – | -$178M | – | – | $-3.66 |
| 2023 | – | -$72M | – | – | $-1.99 |
| 2022 | – | -$30M | – | – | $-5.77 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for MLYS
- 8-K · Oct 29, 2026Material agreement, Agreement terminated
- 8-K · Oct 19, 2026Officer or director change, Financial statements and exhibits
- 10-Q · Aug 11, 2026
- 8-K · Aug 11, 2026Results of operations, Officer or director change, Financial statements and exhibits
- 8-K · Jun 3, 2026Other events, Financial statements and exhibits
- 424B5 · Jun 3, 2026
- 8-K · Jun 3, 2026Material agreement, New financial obligation
- 8-K · May 22, 2026Shareholder vote, Financial statements and exhibits
- 10-Q · May 6, 2026
- 8-K · May 6, 2026Results of operations, Financial statements and exhibits
Insider filing activity
MLYS insiders filed 9 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
MLYS news
- Kidney Trial Results Could Change The Case For Mineralys Therapeutics StockNov 1, 2026 · finance.yahoo.com
- Mineralys Consolidates Full Lorundrostat IP Ownership RightsOct 30, 2026 · theglobeandmail.com
- Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026Oct 28, 2026 · finance.yahoo.com
- Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney InternationalOct 28, 2026 · finance.yahoo.com
- Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026Oct 22, 2026 · finance.yahoo.com
- Mineralys Therapeutics expands board with new independent directorsOct 20, 2026 · theglobeandmail.com
- Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel CoatsOct 19, 2026 · finance.yahoo.com
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. (MLYS) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. Its fiscal year ends in December.